A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis

Temozolomide (TMZ) is the first-line chemotherapy drug that has been used to treat glioma for over a decade, but the benefits are limited by half of the treated patients who acquired resistance. Studies have shown that glioma TMZ resistance is a complex process with multiple factors, which has not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zhifang, Mi, Yajing, Qian, Huiming, Guo, Na, Yan, Aili, Zhang, Yuelin, Gao, Xingchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324762/
https://www.ncbi.nlm.nih.gov/pubmed/32656078
http://dx.doi.org/10.3389/fonc.2020.00897
Descripción
Sumario:Temozolomide (TMZ) is the first-line chemotherapy drug that has been used to treat glioma for over a decade, but the benefits are limited by half of the treated patients who acquired resistance. Studies have shown that glioma TMZ resistance is a complex process with multiple factors, which has not been fully elucidated. Ferroptosis, which is a new type of cell death discovered in recent years, has been reported to play an important role in tumor drug resistance. The present study reviews the relationship between ferroptosis and glioma TMZ resistance, and highlights the role of ferroptosis in glioma TMZ resistance. Finally, the investigators discussed the future orientation for ferroptosis in glioma TMZ resistance, in order to promote the clinical use of ferroptosis induction in glioma treatment.

Ejemplares similares